Medy-Tox   Report issue

For profit Phase 3 Phase 4
Founded: Seoul Korea, Republic of (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2009
NCT01237977
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Medy-Tox | Medytox Korea

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharospasm (Phase 4)

Cerebral Palsy (Phase 4)

Dystonia (Phase 3)

Dystonic Disorders (Phase 3)

Hyperhidrosis (Phase 3)

Hypertrophy (Phase 3)

Muscle Spasticity (Phase 4)

Neuralgia (Phase 4)

Polyneuropathies (Phase 1)

Spinal Cord Injuries (Phase 4)

Torticollis (Phase 3)

Urinary Bladder, Overactive (Phase 3)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 7